Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy

European Urology

Volumn 54, Issue 5, 2008, Pages 1081-1088

  Haese, Alexander ^a   de la Taille, Alexandre ^b   van Poppel, Hendrik ^c   Marberger, Michael ^d   Stenzl, Arnulf ^e   Mulders, Peter F A ^f   Huland, Hartwig ^a   Abbou, Clément Claude ^b   Remzi, Mesut ^d   Tinzl, Martina ^d   Feyerabend, Susan ^e   Stillebroer, Alexander B ^f   van Gils, Martijn P M Q ^f   Schalken, Jack A ^f  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diagnostic methods; PCA3; Prostate biopsy; Prostate cancer; Prostate specific antigen; Sensitivity; Specificity

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER GRADING; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PCA3 GENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; SENSITIVITY AND SPECIFICITY; TUMOR GENE; TUMOR VOLUME; URINALYSIS;

EID: 55649120679     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.071     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Seitz C., Palermo S., and Djavan B. Prostate biopsy. Minerva Urol Nefrol 55 (2003) 205-218
3. Raja J., Ramachandran N., Munneke G., and Patel U. Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. Clin Radiol 61 (2006) 142-153
4. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
5. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
6. PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16
7. Shaw G., Oliver R.T.D., Purkiss T., and Prowse D.M. Re: Christine McKillop. Interview with Jack Schalken: PCA3 and its use as a diagnostic test in prostate cancer. Eur Urol 50 (2006) 153-154 Eur Urol 2007;51:860-2
8. McKillop C. Interview with Jack Schalken: PCA3 and its use as a diagnostic test in prostate cancer. Eur Urol 50 (2006) 153-154
9. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
10. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 69 (2007) 532-535
11. Catalona W.J., Partin A.W., Slawin K.M., et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 279 (1998) 1542-1547
12. Djavan B., Zlotta A., Remzi M., et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol 163 (2000) 1144-1148
13. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
14. Bastian P.J., Mangold L.A., Epstein J.I., and Partin A.W. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 101 (2004) 2001-2005
15. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 179 (2008) 1587-1592
16. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809
17. Brawer M.K. Prostatic intraepithelial neoplasia: an overview. Rev Urol 7 Suppl 3 (2005) S11-S18
18. Herawi M., Kahane H., Cavallo C., and Epstein J.I. Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled. J Urol 175 (2006) 121-124
19. Schoenfield L., Jones J.S., Zippe C.D., et al. The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer. BJU Int 99 (2007) 770-774
20. Popa I., Fradet Y., Beaudry G., et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 20 (2007) 1121-1127
21. Joniau S., Goeman L., Roskams T., et al. Effect of nutritional supplement challenge in patients with isolated high-grade prostatic intraepithelial neoplasia. Urology 69 (2007) 1102-1106